Article info
PDFBrief report
Institution animal care and use committees need greater ethical diversity
- Correspondence to Dr Lawrence Arthur Hansen, Department of Neurosciences and Pathology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA, 92093-0624, USA; lahansen{at}ucsd.edu
Citation
Institution animal care and use committees need greater ethical diversity
Publication history
- Received July 27, 2012
- Revised September 25, 2012
- Accepted October 18, 2012
- First published November 6, 2012.
Online issue publication
April 15, 2018
Article Versions
- Previous version (31 July 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
Other content recommended for you
- Reforming the politics of animal research
- Diversity and inclusion for rodents: how animal ethics committees can help improve translation
- M1 macrophages are required for murine cerebral aneurysm formation
- Animal researchers shoulder a psychological burden that animal ethics committees ought to address
- Xenotransplantation: a bioethical evaluation
- Whistleblowing in academic medicine
- Augmentation of perfusion with simultaneous vasodilator and inotropic agents in experimental acute middle cerebral artery occlusion: a pilot study
- 953 Treatment with SQ3370, a doxorubicin-based therapeutic, corresponds with immunomodulation of the tumor microenvironment
- 478 A novel antagonist monoclonal antibody against human adenosine receptor 2a (A2aR) for cancer immunotherapies
- 11 Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents